Trial · NCT05443802
Comparison of a Low Dose to a Standard Dose of Insulin in Adult DKA in ICU to Reduce Metabolic Complications
NCT05443802, Not applicable, Completed, Assistance Publique - Hôpitaux de Paris
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Comparison of a Low Dose to a Standard Dose of Insulin in Adult DKA in ICU to Reduce Metabolic Complications. Trials, record NCT05443802. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05443802
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Comparison of a Low Dose to a Standard Dose of Insulin in Adult DKA in ICU to Reduce Metabolic Complications
- NCT number
- NCT05443802
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 150 participants, actual
- Lead sponsor
- Assistance Publique - Hôpitaux de Paris
- Conditions
- Diabetic Ketoacidosis
- Interventions
- Insulin 0.05 IU/kg/h, Insulin 0.10 IU/kg/h
- First posted
- 2022-07-05
- Last updated
- 2025-05-29
Source ClinicalTrials.gov
Registered outcomes23
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Metabolic complications | 48 hours | Proportion of patients with metabolic complications (hypokalaemia \<3.5 mmol/L and/or hypoglycemia \<3.9 mmol/L) treated with a reduced dose of insulin (0.05 IU/kg/h) compared with the control group receiving the 0.10 IU/kg/h dose. |
| Secondary | Resolution of diabetic ketoacidosis | 48 hours | Time in hours between randomisation and resolution of diabetic ketoacidosis (defined by ph\>7.3 and ketonemia \< 3 mmol/L and bicarbonates\> 15 mmol/L) |
| Secondary | Episode of hypokalaemia | 48 hours | Proportion of patients with at least one episode of hypokalaemia \< 3.5 mmol/L between randomization and resolution of DKA |
| Secondary | Episode of hypoglycemia | 48 hours | Proportion of patients with at least one episode of hypoglycemia \< 3.9 mmol/L between randomization and resolution of DKA |
| Secondary | Episode of severe hypoglycemia | 48 hours | Proportion of patients with at least one episode of hypoglycemia \< 2.9 mmol/L between randomization and resolution of DKA |
| Secondary | Cardiac arrythmia diagnosed by EKG | 48 hours | Proportion of patients with onset of new cardiac arrhythmia diagnosed by EKG analysis (atrial fibrillation and ventricular arrhythmia) and scopic monitoring between randomization and resolution of DKA |
| Secondary | Glucose infusion 1000mL | 48 hours | Proportion of patients who received more than 1000 mL of 10% glucose solution (indicating tendency of hypoglycemia) between randomization and resolution of DKA or 48h after inclusion if DKA is unresolved |
| Secondary | Glucose infusion of 30% glucose solution | 48 hours | Proportion of patients who received one perfusion of 30% glucose solution between randomization and resolution of DKA or 48h after inclusion if DKA is unresolved |
| Secondary | Amount of glucose perfused | 48 hours | Amount of glucose perfused (in grams) (glucose 5%, 10% and 30%) between randomization and resolution of the DKA or 48 hours after inclusion if the DKA is not resolved |
| Secondary | Potassium intake | 48 hours | Potassium intake (in grams) orally and intravenously between patient randomization and resolution of DKA or 48 hours after inclusion if DKA is not resolved |
1 to 10 of 23Source ClinicalTrials.gov
See all 23 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05443802
GET https://conductscience.org/api/trials/v1/NCT05443802/registered?page=2